Trial Profile
Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Citalopram (Primary) ; Reboxetine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 22 Mar 2012 Actual initiation date changed from 1 Nov 2008 to 27 Jul 2008 as reported by European Clinical Trials Database.
- 02 Mar 2011 New trial record